Curis, Inc. Share Price Nasdaq
Equities
US2312691015
Biotechnology & Medical Research
Sales 2024 * | 8.61M 718M | Sales 2025 * | 8.96M 748M | Capitalization | 85.29M 7.11B |
---|---|---|---|---|---|
Net income 2024 * | -49M -4.09B | Net income 2025 * | -54M -4.5B | EV / Sales 2024 * | 9.9 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 9.52 x |
P/E ratio 2024 * |
-2.33
x | P/E ratio 2025 * |
-2.81
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.82% |
Latest transcript on Curis, Inc.
Managers | Title | Age | Since |
---|---|---|---|
James Dentzer
CEO | Chief Executive Officer | 57 | 29/16/29 |
Diantha Duvall
DFI | Director of Finance/CFO | 52 | 26/22/26 |
Chief Tech/Sci/R&D Officer | - | 03/22/03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 01/03/01 | |
Chairman | 82 | 14/00/14 | |
James Dentzer
CEO | Chief Executive Officer | 57 | 29/16/29 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |